RedHill Biopharma: Rises on FDA approval for COVID-19 drug study
08/05/2020 13:01
** Shares of Israel-based drug developer RDHL.O jump
13.15% to $7.40 premarket
** Company says U.S. FDA approves clinical study to evaluate
its experimental drug, opaganib, to treat patients with
moderate-to-severe COVID-19 urn:newsml:reuters.com:*:nGNEx7Bw8
** In April, company said six COVID-19 patients who were
given the drug in Israel showed decreased need for supplemental
oxygen and higher blood cell counts
** For the FDA-approved study, company to enroll 40 patients
with COVID-19 and pneumonia, requiring hospitalization and
supplemental oxygen
** Opaganib is an experimental cancer drug being studied for
several forms of the disease including prostate cancer
** Up to Thursday's close, RDHL was down 7.74% YTD
(Reporting by Vishwadha Chander in Bengaluru)
((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))